• PCV61 COST EFFECTIVENESS OF RIVAROXABAN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION PATIENTS FOR TTR AND CHADS2 SCORE IN TURKEY

    Nov 1, 2019, 00:00 AM

  • PCN141 USE OF COST-EFFECTIVENESS AFFORDABILITY CURVES IN EVALUATING CANCER DRUGS IN ENGLAND

    Nov 1, 2019, 00:00 AM

  • PMU53 THE INCENTIVE FINANCIAL FRAMEWORK REGARDING FRENCH HOSPITAL PRESCRIPTION OF BIOSIMILAR MEDICINES WHEN DELIVERED IN RETAIL PHARMACY: IMPACT ANALYSIS OF ARTICLE 51 EXPERIMENTATION FOR 2018

    Nov 1, 2019, 00:00 AM

  • PNS20 RECENT ADVANCES IN THE EUROPEAN CROSS-BORDER COLLABORATIONS IN JOINT DRUG PROCUREMENT LANDSCAPE

    Nov 1, 2019, 00:00 AM

  • PCN324 PRELIMINARY EVIDENCE SUGGESTS THAT WE MOVE TOWARDS THE USE OF LIQUID BIOPSIES TO PREDICT RESPONSE TO TKI INHIBITORS: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00 AM

  • PCV92 ANALYSING DATA OF PATIENTS WITH ACUTE MYOCARDIAL INFARCTION ACCORDING TO PROGRESSIVITY LEVELS IN HUNGARY (COMPARISON OF 2013 AND 2018)

    Nov 1, 2019, 00:00 AM

  • PCN487 COST OF PROSTATE CANCER AND QUALITY OF LIFE IN EGYPT - A PATIENT PERSPECTIVE STUDY

    Nov 1, 2019, 00:00 AM

  • PMS78 CANADIAN REAL-WORLD EVIDENCE ON EPIDEMIOLOGY, OUTCOMES AND ECONOMICS OF MODERATE-TO-SEVERE OSTEOARTHRITIS: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00 AM

  • PIN43 LIFECYCLE-MODEL-BASED ECONOMIC EVALUATION OF INFANT MENINGITIS B VACCINATION IN THE UK

    Nov 1, 2019, 00:00 AM

  • Diabetes/Endocrine/Metabolic Disorders - Methodological Statistical Research

    Nov 1, 2019, 00:00 AM

  • Musculoskeletal Disorders - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00 AM

  • PCN15 PROPHYLAXIS FOR BICALUTAMIDE-INDUCED GYNECOMASTIA: A NETWORK META-ANALYSIS

    Nov 1, 2019, 00:00 AM

  • PCN144 ECONOMIC EVALUATIONS OF CANCER INTERVENTIONS IN SPAIN: LITERATURE REVIEW

    Nov 1, 2019, 00:00 AM

  • PCN299 MINIMUM VOLUME STANDARDS IN FRENCH HOSPITALS FOR BREAST CANCER AND OVARIAN CANCER - INEQUALITIES IN ACCESS TO HOSPITAL CARE

    Nov 1, 2019, 00:00 AM

  • PCV51 COST-EFFECTIVENESS OF RIVAROXABAN IN THE TREATMENT OF PATIENTS WITH CHRONIC CAD OR PAD IN THE UK

    Nov 1, 2019, 00:00 AM

  • PCV50 COST-EFFECTIVENESS OF TARGETED SCREENING USING A MACHINE LEARNING RISK PREDICTION TOOL FOR THE IDENTIFICATION OF PATIENTS WITH ATRIAL FIBRILLATION

    Nov 1, 2019, 00:00 AM

  • PIH29 SELF- MEDICATION: ASSESSMENT OF PRACTICES AMONG PREGNANT WOMEN

    Nov 1, 2019, 00:00 AM

  • PND9 UPDATED META-ANALYSIS OF THE EFFICACY OF ADJUVANT TREATMENT TO LEVODOPA IN PARKINSON'S DISEASE

    Nov 1, 2019, 00:00 AM

  • PCN486 REGULATORY SUCCESS IN LABELLING HRQOL AND SYMPTOMS FOR NSCLC THERAPIES

    Nov 1, 2019, 00:00 AM

  • PGI23 COST OF INFLAMMATORY BOWEL DISEASE MANAGEMENT IN THE KINGDOM OF SAUDI ARABIA

    Nov 1, 2019, 00:00 AM

  • Sensory System Disorders - Health Technology Assessment

    Nov 1, 2019, 00:00 AM

  • Systemic Disorders/Conditions - Epidemiology Public Health

    Nov 1, 2019, 00:00 AM

  • PIN74 A NEW WAY TO INFORM DECISION-MAKER AND ENHANCE VACCINATION PROGRAMS IN COUNTRIES WITH LIMITED BUDGETS: THE CASE OF SERBIA

    Nov 1, 2019, 00:00 AM

  • Cancer - Clinical Outcomes

    Nov 1, 2019, 00:00 AM

  • PCN485 PATIENT-REPORTED OUTCOMES AND THEIR RELATIONSHIP WITH CLINICAL OUTCOMES IN PATIENTS WITH FLT3-MUTATED (FLT3 MUT+) RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM THE PHASE 3 ADMIRAL STUDY

    Nov 1, 2019, 00:00 AM

  • PRO120 EVOLUTION OF OBCS NECESSARY TO ACTIVATE VALUE WITHIN STEM CELL RARE DISEASES

    Nov 1, 2019, 00:00 AM

  • PNS302 IMPROVING THE PERFORMANCE OF PATIENT-LEVEL SIMULATION MODELS USING MULTI-THREADING AND SINGLE INSTRUCTION MULTIPLE DATA (SIMD) OPERATIONS

    Nov 1, 2019, 00:00 AM

  • PMU52 ANALYSIS OF THE REIMBURSEMENT DECISIONS MADE BY THE INTERMINISTERIAL PRICE COMMISSION FOR MEDICINES IN SPAIN

    Nov 1, 2019, 00:00 AM

  • PNS266 DIFFERENT INTERPRETATION OF ADDITIONAL EVIDENCE FOR HTA BY THE COMMISSIONED HTA BODY AND THE COMMISSIONING DECISION MAKER IN GERMANY: WHENEVER IQWIG AND FEDERAL JOINT COMMITTEE DISAGREE

    Nov 1, 2019, 00:00 AM

  • PMU45 PREVALENCE VS. TREATMENT COST: ANALYSIS OF DRUGS FOR RARE DISEASE IN ITALY

    Nov 1, 2019, 00:00 AM

  • PCN330 A COMPARISON OF HEALTHCARE AND SOCIETAL COSTS OF HOSPITAL-BASED AND HOME-BASED SUBCUTANEOUS INJECTIONS OF TRASTUZUMAB

    Nov 1, 2019, 00:00 AM

  • PCN327 KEY INTERVALS IN THE PATIENT JOURNEY OF MEN WITH PROSTATE CANCER: EVIDENCE FROM GREECE

    Nov 1, 2019, 00:00 AM

  • Surgery - Medical Technologies

    Nov 1, 2019, 00:00 AM

  • PCN52 ABIRATERONE VERSUS ENZALUTAMIDE IN THE POST-CHEMOTHERAPY SETTING IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: POPULATION-BASED STUDY

    Nov 1, 2019, 00:00 AM

  • PND51 PRODUCTIVITY LOSS IN NHS HOSPITALS DUE TO DIFFICULT-TO-TREAT MIGRAINE

    Nov 1, 2019, 00:00 AM

  • PCV66 NATIONWIDE ANNUAL HEALTH INSURANCE TREATMENT COST OF ARTERIAL EMBOLISM AND THROMBOSIS IN HUNGARY: COST OF ILLNESS STUDY BASED ON REAL WORLD DATA

    Nov 1, 2019, 00:00 AM

  • PGI12 COST PER RESPONDER ANALYSIS EVALUATED THROUGH CLINICAL RESPONSE AND REMISSION RATE OF ADALIMUMAB, USTEKINUMAB AND VEDOLIZUMAB FOR THE TREATMENT OF CROHN'S DISEASE IN BIOLOGIC NAIVE PATIENTS FROM THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM ...

    Nov 1, 2019, 00:00 AM

  • PMU30 A SYSTEMATIC REVIEW OF PREVIOUSLY PUSBLISHED OR APPRAISED HEALTH ECONOMIC MODELS ESTIMATING THE SHORT- AND LONG-TERM CONSEQUENCES OF STEROID-SPARING AGENTS

    Nov 1, 2019, 00:00 AM

  • PMD37 EVOLUTION OF UNION EUROPEAN MEDICAL DEVICE REGULATION: PERSPECTIVE WITH THE CLINICAL EVALUATION OF DUAL MOBILITY ACETABULAR CUPS BY THE FRENCH NATIONAL HEALTH TECHNOLOGY ASSESSMENT AGENCY

    Nov 1, 2019, 00:00 AM

  • PUK30 COMPARING SOFTWARE FOR PATIENT-LEVEL SIMULATION: REPLICATING A MODEL OF HYPERPHOSPHATAEMIA IN CHRONIC KIDNEY DISEASE

    Nov 1, 2019, 00:00 AM

  • PUK3 TREATMENT EFFECTS IN SECONDARY HYPERPARATHYROIDISM IN NON-DIALYSIS CHRONIC KIDNEY DISEASE: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00 AM

  • Surgery - Economic Evaluation

    Nov 1, 2019, 00:00 AM

  • PIN49 BURDEN OF S. AUREUS, E. COLI, K. PNEUMONIAE ASSOTIATED INFECTIONS IN RUSSIAN FEDERATION

    Nov 1, 2019, 00:00 AM

  • PCN239 MEDICAL COST OF RITUXIMAB-CONTAINING THERAPY IN PATIENTS WITH FOLLICULAR LYMPHOMA IN JAPAN: R-B IS LESS EXPENSIVE THAN R-CHOP

    Nov 1, 2019, 00:00 AM

  • PNS368 THE EVOLVING ROLE OF PATIENT ADVOCACY IN DRUG APPRAISAL AND COMMISSIONING: PERSPECTIVES FROM ENGLAND

    Nov 1, 2019, 00:00 AM

  • PMH2 BREXANOLONE INJECTION IN POSTPARTUM DEPRESSION: SUSTAINED REMISSION, SUSTAINED RESPONSE, AND NUMBER NEEDED TO TREAT

    Nov 1, 2019, 00:00 AM

  • PNS138 TRANSNATIONAL COLLABORATIONS AMONG DRUG REGULATORY AGENCIES: TRENDS AND FUTURE PERSPECTIVES

    Nov 1, 2019, 00:00 AM

  • PIN77 EFFICACY MISAPPLICATION IN VACCINE MODELLING

    Nov 1, 2019, 00:00 AM

  • PCN146 VALIDATION OF PREDICTED SURVIVAL ESTIMATES FROM PREVIOUS DATA CUTS OF THE PHASE III CHECKMATE 025 STUDY IN ADVANCED RENAL CELL CARCINOMA

    Nov 1, 2019, 00:00 AM

  • PCV17 HEALTHCARE UTILIZATION PRIOR TO AN INITIAL DIAGNOSIS OF PAROXYSMAL SUPRVENTRICULAR TACHYCARDIA IN A LARGE HEALTHCARE SYSTEM

    Nov 1, 2019, 00:00 AM

  • Cardiovascular Disorders - Clinical Outcomes

    Nov 1, 2019, 00:00 AM

  • Medical Devices - Health Technology Assessment

    Nov 1, 2019, 00:00 AM

  • PRO117 ACCESS TO ORPHAN DRUGS IN THE UNITED KINGDOM: A REVIEW OF NICE DECISIONS FROM 2017-2018

    Nov 1, 2019, 00:00 AM

  • PCN164 COST-EFFECTIVENESS OF DACOMITINIB VS. GEFITINIB AS FIRST-LINE TREATMENT FOR EGFR MUTATION POSITIVE ADVANCED NON-SMALL-CELL LUNG CANCER IN CHINA

    Nov 1, 2019, 00:00 AM

  • PCN465 VIRTUAL COMMUNITY ENGAGEMENT AMONG WOMEN RECEIVING PALBOCICLIB FOR HR+/ HER2- METASTATIC BREAST CANCER: DATA FROM THE MADELINE STUDY

    Nov 1, 2019, 00:00 AM

  • PND101 AN UPDATE OF A SYSTEMATIC REVIEW: ATTRIBUTE BASED STATED PREFERENCE STUDIES IN MULTIPLE SCLEROSIS PATIENTS

    Nov 1, 2019, 00:00 AM

  • PCN481 METHODOLOGICAL ASPECTS OF HEALTH-RELATED QUALITY OF LIFE MEASUREMENT IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER IN CLINICAL TRIALS: A SYSTEMATIC REVIEW.

    Nov 1, 2019, 00:00 AM

  • Medical Devices - Real World Data Information Systems

    Nov 1, 2019, 00:00 AM

  • PMU130 REPRESENTATIVENESS OF THE NATIONAL HEALTH AND WELLNESS SURVEY IN EUROPE: CURRENT EPIDEMIOLOGY ACROSS MULTIPLE DISEASES

    Nov 1, 2019, 00:00 AM

  • PNS6 SYSTEMATIC LITERATIVE REVIEW AND QUALITATIVE ANALYSIS ASSESSING EFFICACY AND SAFETY OF INTERVENTIONS IN ACTINIC KERATOSIS

    Nov 1, 2019, 00:00 AM

  • PBI14 COST-EFFECTIVENESS OF SECUKINUMAB VERSUS OTHER BIOLOGICS AND APREMILAST IN THE TREATMENT OF ACTIVE PSORIATIC ARTHRITIS: A SPANISH PERSPECTIVE

    Nov 1, 2019, 00:00 AM

  • PIH28 A REAL WORLD ANALYSIS OF PREVALENCE OF SYMPTOMS AND HEALTHCARE UTILIZATION IN WOMEN WITH MENOPAUSE

    Nov 1, 2019, 00:00 AM

  • PCN185 PERTUZUMAB RISK SHARING AGREEMENT IN THE PORTUGUESE NHS: A 4-YEAR EXPERIENCE

    Nov 1, 2019, 00:00 AM

  • PGI30 THE MEDICAL COSTS OF INFLAMMATORY BOWEL DISEASE IN RUSSIA FROM A PUBLIC PAYER PERSPECTIVE

    Nov 1, 2019, 00:00 AM

  • PSU15 COST-EFFECTIVENESS OF SHOULDER ARTHROPLASTY: A PROSPECTIVE STUDY USING REAL-WORLD DATA FROM SWITZERLAND

    Nov 1, 2019, 00:00 AM

  • PNS176 COMPARISON OF HOSPITAL BED NUMBERS IN EUROPEAN OECD COUNTRIES WITH BISMARCK- AND BEVERIDGE HEALTH CARE MODELS

    Nov 1, 2019, 00:00 AM

  • PCV100 THE RELATIONSHIP BETWEEN PROCEDURAL VOLUME AND POSTOPERATIVE MORTALITY FOR PERCUTANEOUS CORONARY INTERVENTIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS

    Nov 1, 2019, 00:00 AM

  • PCN460 SYSTEMATIC LITERATURE REVIEW FOR UTILITY DATA IN ACUTE MYELOID LEUKEMIA

    Nov 1, 2019, 00:00 AM

  • PND68 ASSOCIATION BETWEEN HEPATITIS C VIRUS INFECTION AND PARKINSON'S DISEASE IN PATIENTS FOLLOWED BY GENERAL PRACTITIONERS IN GERMANY

    Nov 1, 2019, 00:00 AM

  • Projected Cost-Effectiveness for 2 Gene-Drug Pairs Using a Multigene Panel for Patients Undergoing Percutaneous Coronary Intervention

    Nov 1, 2019, 00:00 AM

  • PCN496 BURDEN OF ACUTE MYELOID LEUKEMIA AMONG NEWLY DIAGNOSED PATIENTS IN SOUTH KOREA: RETROSPECTIVE EMR DATABASE ANALYSIS

    Nov 1, 2019, 00:00 AM

  • PBI9 SYSTEMATIC LITERATURE REVIEW OF NMAS AND POPULATION ADJUSTED INDIRECT COMPARISONS OF BIOLOGICAL TREATMENTS IN MODERATE-TO-SEVERE PSORIASIS

    Nov 1, 2019, 00:00 AM

  • PNS396 VALUING HEALTH RELATED QUALITY OF LIFE IN MOROCCO: AN EQ-5D-3L VALUE SET

    Nov 1, 2019, 00:00 AM

  • PCN20 ACCURATE PREDICTIONS OF LIFE YEAR GAINS FOR IMMUNO-ONCOLOGY THERAPIES IN THE LONG TERM? AN ANALYSIS BASED ON PUBLISHED CHECKMATE 057 NIVOLUMAB DATA

    Nov 1, 2019, 00:00 AM

  • PNS235 ASSESSMENT OF DIGITAL HEALTH TECHNOLOGIES - COMPARISON OF EVIDENCE FRAMEWORKS OF NICE AND HAS

    Nov 1, 2019, 00:00 AM

  • PCN254 CHARACTERISING INDIVIDUALS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER USING ROUTINE LINKED HEALTH DATASETS: A FEASIBILITY STUDY

    Nov 1, 2019, 00:00 AM

  • PCN503 USE OF HEALTH ECONOMICS AND OUTCOMES RESEARCH TO INFORM TREATMENT DECISIONS AMONG US ONCOLOGISTS

    Nov 1, 2019, 00:00 AM

  • PRO56 ECONOMIC IMPACT OF THE INTRODUCTION OF RFVIII-SINGLECHAIN (AFSTYLA®) FOR THE TREATMENT OF HEMOPHILIA A IN ITALY

    Nov 1, 2019, 00:00 AM

  • CP2 DO SOCIAL VALUES AND INSTITUTIONAL CONTEXT IMPACT THE USE OF ECONOMIC EVALUATION IN PRIORITY SETTING: EMPIRICAL EVIDENCE FROM OECD COUNTRIES

    Nov 1, 2019, 00:00 AM

  • PNS18 CAN REFLECTIVE MCDA CONTRIBUTE TO ACHIEVING EMA'S STRATEGIC OBJECTIVES FOR REGULATORY SCIENCE TO 2025? WHEN THE BOTTOM UP APPROACH CAN BE THE WAY TO GO: INSIGHTS FROM SPANISH EXPERIENCE

    Nov 1, 2019, 00:00 AM

  • PCN55 NETWORK META-ANALYSIS COMPARING PALBOCICLIB PLUS FULVESTRANT WITH EVEROLIMUS PLUS EXEMESTANE FOR HR+/HER2- ADVANCED BREAST CANCER THAT HAS BECOME RESISTANT TO PREVIOUS ENDOCRINE THERAPY

    Nov 1, 2019, 00:00 AM

  • Personalized Process of Care

    Nov 1, 2019, 00:00 AM

  • PCN356 ARE CANCER DRUGS ASSOCIATED WITH A COMPANION DIAGNOSTIC TEST TAKING LONGER TO BE REIMBURSED IN AUSTRALIA?

    Nov 1, 2019, 00:00 AM

  • PCN422 BAYESIAN MODEL AVERAGING FOR EXTRAPOLATING SURVIVAL: A PAN-TUMOR PERSPECTIVE ON NIVOLUMAB AND IPILIMUMAB

    Nov 1, 2019, 00:00 AM

  • PNS359 INTERNATIONAL OBSERVATIONAL STUDIES: THE INCREASED NEED FOR A COMMON EUROPEAN REGULATION

    Nov 1, 2019, 00:00 AM

  • PND47 CLADRIBINE TABLET, AS A DOMINANT COMPARATOR TO NATALIZUMAB IN HIGH-DISEASE ACTIVITY RELAPSING MULTIPLE SCLEROSIS PATIENTS, IN THE CONTEXT OF A DEVELOPING COUNTRY

    Nov 1, 2019, 00:00 AM

  • PCN467 THE HUMANISTIC BURDEN OF MULTIPLE MYELOMA IN NEWLY DIAGNOSED PATIENTS: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00 AM

  • PRO107 UNDERSTANDING THE PRICING AND REIMBURSEMENT (PR) LANDSCAPE OF ORPHAN DRUGS IN EMERGING MARKETS

    Nov 1, 2019, 00:00 AM

  • PRO29 COST-EFFECTIVENESS OF VORETIGENE NEPARVOVEC FOR VISION LOSS DUE TO BIALLELIC RPE65-MEDIATED INHERITED RETINAL DISEASE IN A DANISH SETTING

    Nov 1, 2019, 00:00 AM

  • PNS288 ANALYSIS OF RECENT TRENDS IN E-HEALTH SOLUTIONS DEVELOPED BY PHARMACEUTICAL AND BIOTECH COMPANIES

    Nov 1, 2019, 00:00 AM

  • Cancer - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00 AM

  • PNS278 A REVIEW OF HEALTH TECHNOLOGY ASSESSMENT GUIDELINES ON THE APPROVAL OF BIOSIMILARS

    Nov 1, 2019, 00:00 AM

  • PCV117 DESIGNING THE NEXT TRIAL FROM NETWORK META-ANALYSES USING SIMULATION-BASED ASSURANCE CALCULATIONS

    Nov 1, 2019, 00:00 AM

  • PND43 BUDGET IMPACT OF THE INTRODUCTION OF ALEMTUZUMAB IN NORWAY; A REAL WORLD EVIDENCE ANALYSIS USING DATA FROM THE NORWEGIAN PATIENT REGISTRY, THE NORWEGIAN PRESCRIPTION DATABASE, AND IMS SALES DATA

    Nov 1, 2019, 00:00 AM

  • Gastrointestinal Disorders - Health Policy Regulatory

    Nov 1, 2019, 00:00 AM

  • PDB125 PREDICTING NASH PATIENTS USING INNOVATIVE MACHINE LEARNING TECHNIQUES

    Nov 1, 2019, 00:00 AM

  • PCN165 A GERMAN COST ANALYSIS OF TRIPLET REGIMENS FOR RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS

    Nov 1, 2019, 00:00 AM

  • PSY17 REAL-WORLD COST DIFFERENCE IN PATIENTS WITH PSORIASIS NEWLY INITIATING APREMILAST VS. BIOLOGIC TREATMENT AFTER CONVENTIONAL SYSTEMIC THERAPY: A RETROSPECTIVE ANALYSIS OF GERMAN SICKNESS FUND DATA

    Nov 1, 2019, 00:00 AM

  • PRO85 THE APPRAISAL PROCESS OF HIGH COST DRUGS FOR RARE GENETIC DISEASES IN THE PUBLIC HEALTH SYSTEM IN BRAZIL

    Nov 1, 2019, 00:00 AM

  • PMU140 A COMPREHENSIVE CATALOGUE OF EQ-5D SCORES IN CHRONIC DISEASE: RESULTS OF A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00 AM

  • PNS392 THE ROLE OF PATIENTS IN THE UPTAKE OF PHARMACEUTICAL PRODUCTS BY PATIENTS AS PERCEIVED BY PROFESSIONALS

    Nov 1, 2019, 00:00 AM

  • PNS35 MULTI-NATIONAL NORDIC PHARMACOEPIDEMIOLOGIC STUDIES: OPPORTUNITIES AND CHALLENGES

    Nov 1, 2019, 00:00 AM

  • PNS213 NICE FAST TRACK APPRAISALS: A DESCRIPTIVE OVERVIEW

    Nov 1, 2019, 00:00 AM

  • PCN301 PATIENT ACCESS TO PERSONALIZED ONCOLOGY MEDICINES IN TURKEY

    Nov 1, 2019, 00:00 AM

  • Urinary/Kidney Disorders - Methodological Statistical Research

    Nov 1, 2019, 00:00 AM

  • PDB43 COST COMPARISON OF GLICAZIDE MODIFIED-RELEASE AND GENERIC GLICLAZIDE IN PREVENTING END STAGE RENAL DISEASE IN TYPE 2 DIABETES MELLITUS IN THE PUBLIC SECTOR OF MALAYSIA

    Nov 1, 2019, 00:00 AM

  • PRS60 IMPACT OF SLEEP DISTURBANCE ON HEALTH-RELATED QUALITY OF LIFE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD): WHAT DO WE KNOW SO FAR?

    Nov 1, 2019, 00:00 AM

  • PCN320 ADMINISTRATIVE OVERSIGHT SHORTENS WAIT-TIME TO BEGIN RADIOTHERAPY IN THE PUBLIC SYSTEM

    Nov 1, 2019, 00:00 AM

  • PCN248 COST-UTILITY ANALYSIS OF FIRST-LINE THERAPY FOR ADVANCED AND METASTATIC PANCREATIC CANCER IN JAPAN.

    Nov 1, 2019, 00:00 AM

  • PRO135 PROJECT HERCULES: A SYSTEMATIC REVIEW OF THE CONTENT AND STRUCTURAL VALIDITY OF PROS USED TO ASSESS QUALITY OF LIFE IN DUCHENNE MUSCULAR DYSTROPHY (DMD)

    Nov 1, 2019, 00:00 AM

  • PCN35 SURVEILLANCE FOR PATIENTS WITH LI-FRAUMENI SYNDROME

    Nov 1, 2019, 00:00 AM

  • PGI31 SENSITIVITY OF INCREASING BODY WEIGHT IN PATIENTS WITH COLLITIS ULCEROSA TO TOTAL COST OF TREATMENT

    Nov 1, 2019, 00:00 AM

  • PCN474 MAPPING PATIENT INVOLVEMENT IN NICE APPRAISALS OF ONCOLOGY PRODUCTS

    Nov 1, 2019, 00:00 AM

  • PCN222 CARFILZOMIB/LENALIDOMIDE/DEXAMETHASONE IN THE SECOND-LINE SETTING FOLLOWED BY DARATUMUMAB/LENALIDOMIDE/DEXAMETHASONE IN THE THIRD-LINE SETTING VERSUS THE OPPOSITE TREATMENT SEQUENCE: A COST COMPARISON STUDY FROM A BRAZILIAN PRIVATE H ...

    Nov 1, 2019, 00:00 AM

  • PMS20 COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB IN ANKYLOSING SPONDYLITIS IN BIOLOGIC-EXPERIENCED PATIENTS FROM THE PORTUGUESE PERSPECTIVE

    Nov 1, 2019, 00:00 AM

  • PNS121 PRIVATE HEALTH INSURANCE COLLABORATION WITH PHARMACEUTICAL COMPANIES IN EGYPT

    Nov 1, 2019, 00:00 AM

  • Respiratory-Related Disorders - Patient-Centered Research

    Nov 1, 2019, 00:00 AM

  • PIN71 PURSUING ELIMINATION OF HEPATITIS C IN EGYPT: AN ECONOMIC EVALUATION OF A COUNTRY-WIDE PROGRAM AND ITS ASSOCIATED COST EFFECTIVENESS

    Nov 1, 2019, 00:00 AM

  • PCN247 COST-EFFECTIVENESS OF PERTUZUMAB PLUS TRASTUZUMAB VS TRASTUZUMAB IN NEOADJUVANT SETTING BASED ON THE NEOSPHERE TRIAL IN TURKEY

    Nov 1, 2019, 00:00 AM

  • PCV83 EPIDEMIOLOGY OF STABLE CORONARY ARTERY DISEASE AND OF PERIPHERAL ARTERY DISEASE IN PORTUGAL

    Nov 1, 2019, 00:00 AM

  • PMU66 TIMEFRAME FOR DRUG MARKETING AUTHORIZATION IN EUROPE

    Nov 1, 2019, 00:00 AM

  • PCN50 INDIRECT COMPARISON OF PARP INHIBITORS IN OVARIAN CANCER: NETWORK META-ANALYSIS

    Nov 1, 2019, 00:00 AM

  • Individual's Health - Health Technology Assessment

    Nov 1, 2019, 00:00 AM

  • PUK38 PATTERN OF TREATMENT AND HEALTHCARE COSTS OF SECONDARY HYPERPARATHYROIDISM IN DIALYSIS PATIENTS: A REAL-WORLD EVIDENCE ANALYSIS

    Nov 1, 2019, 00:00 AM

  • PCN443 INDIRECT COMPARISON BETWEEN REAL WORLD DATA AND CLINICAL TRIAL IN NON SMALL CELL LUNG CANCER WITH BEVACIZUMAB

    Nov 1, 2019, 00:00 AM

  • PCN524 EUROPEAN REAL-WORLD TREATMENT PATTERNS OF SYSTEMIC THERAPIES FOR SECOND LINE (2L) HEPATOCELLULAR CARCINOMA (HCC) PATIENTS WHO PREVIOUSLY RECEIVED SORAFENIB

    Nov 1, 2019, 00:00 AM

  • PCN114 ASSESSMENT OF THE SURVIVAL BENEFIT AND COST IMPACT OF NEW TREATMENTS FOR KEY ANSCLC BIOMARKERS USING THE ITEN MODEL

    Nov 1, 2019, 00:00 AM

  • PIN143 MEASUREMENT OF HEALTH RELATED QUALITY OF LIFE IN TUBERCULOSIS PATIENTS USING SPECIFIC AND GENERIC INSTRUMENTS

    Nov 1, 2019, 00:00 AM

  • PCN143 COMPARISON OF ADVERSE EVENT COSTS OF NIVOLUMAB+IPILIMUMAB VERSUS SUNITINIB FOR PREVIOUSLY UNTREATED INTERMEDIATE-/POOR-RISK ADVANCED RENAL CELL CARCINOMA IN PORTUGAL

    Nov 1, 2019, 00:00 AM

  • PRO46 EMICIZUMAB PROPHYLAXIS IS A COST-SAVING OPTION FOR HEMOPHILIA A PATIENTS WITH INHIBITORS IN KOREA: A COST-EFFECTIVENESS ANALYSIS

    Nov 1, 2019, 00:00 AM

  • PCN373 RECENT COST PER QALY TRENDS OF NON-HAEMATOLOGICAL CANCERS ASSESSMENT AT NICE

    Nov 1, 2019, 00:00 AM

  • PIN6 EVALUATION OF DIRECT-ACTING ANTIVIRALS RETREATMENT IN NON-SUSTAINED VIROLOGICAL RESPONDERS

    Nov 1, 2019, 00:00 AM

  • Diabetes/Endocrine/Metabolic Disorders - Economic Evaluation

    Nov 1, 2019, 00:00 AM

  • PGI3 DEPRESCRIBING OF LONG TERM UTILIZATION OF H2 RECEPTOR ANTAGONISTS AND PROTON PUMP INHIBITORS BASED ON ENDOSCOPIC ANALYSIS

    Nov 1, 2019, 00:00 AM

  • PBI37 BIOSIMILAR INTERCHANGEABILITY, SUBSTITUTION AND SWITCHING: AN OVERVIEW OF 5 EUROPEAN MEMBER STATES AND THE UNITED STATES

    Nov 1, 2019, 00:00 AM

  • PCN110 NATIONWIDE ANNUAL HEALTH INSURANCE TREATMENT COST OF MALIGNANT MELANOMA OF SKIN IN HUNGARY: COST OF ILLNESS PILOT STUDY BASED ON REAL WORLD DATA

    Nov 1, 2019, 00:00 AM

  • PDB16 ASSESSMENT OF COST-EFFECTIVENESS OF A 0.2 ÎœCG/DAY FLUOCINOLONE ACETONIDE (FAC) IMPLANT IN PATIENTS WITH CHRONIC DIABETIC MACULAR OEDEMA (DMO) IN AN EYE WITH CATARACT

    Nov 1, 2019, 00:00 AM

  • PND53 ECONOMIC EVALUATION OF CLADRIBINE TABLETS IN RELAPSING MULTIPLE SCLEROSIS (RMS) PATIENTS WITH HIGH DISEASE ACTIVITY (HDA) IN LEBANON

    Nov 1, 2019, 00:00 AM

  • PND66 ASSESSING THE POTENTIALLY INAPPROPRIATE USE OF ACETYLCHOLINESTERASE INHIBITORS IN ELDERLY PATIENTS WITH PARKINSON DISEASE USING KOREA NATIONAL HEALTH INSURANCE CLAIMS DATA

    Nov 1, 2019, 00:00 AM

  • PCN376 ACCESS TO ONCOLOGY THERAPIES IN RUSSIA AND VISEGRAD GROUP COUNTRIES

    Nov 1, 2019, 00:00 AM

  • PIT10 THE INCREMENTAL COST OF TRAUMATIC BRAIN INJURY DURING THE FIRST YEAR AFTER A ROAD TRAFFIC ACCIDENT IN BELGIUM

    Nov 1, 2019, 00:00 AM

  • PSY49 THE JOURNEY OF THALASSAEMIA PATIENT IN SEEKING TREATMENT IN MALAYSIAN HEALTHCARE

    Nov 1, 2019, 00:00 AM

  • PND39 A COST-EFFECTIVENESS ANALYSIS OF PREGABALIN VS. DULOXETINE IN THE TREATMENT OF FIBROMYALGIA IN CHINA

    Nov 1, 2019, 00:00 AM

  • PIN76 BUDGET IMPACT OF CEFTAZIDIME AVIBACTAM (CAZ-AVI) FOR COMPLICATED INTRA-ABDOMINAL INFECTION, COMPLICATED URINARY TRACT INFECTION AND HOSPITAL-ACQUIRED PNEUMONIA IN SINGAPORE

    Nov 1, 2019, 00:00 AM

  • PDB41 HOW ECONOMIC ANALYSIS INCREASE AWARENESS ON CLINICAL SERVICE, A CASE OF DIABETES MELLITUS AT A TEACHING HOSPITAL IN MYANMAR

    Nov 1, 2019, 00:00 AM

  • PNS63 WILLINGNESS TO PAY FOR HEALTH INSURANCE USING THE CONTINGENT VALUATION METHOD: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00 AM

  • PMS21 PRELIMINARY RESULTS OF A COST-UTILITY ANALYSIS OF A FRACTURE LIAISON SERVICE BASED ON HEALTH SERVICES INDICATORS

    Nov 1, 2019, 00:00 AM

  • PCN452 COMPARING OUTCOMES OF DIFFERENT STANDARD AND NOVEL APPROACHES THAT INCORPORATE GENERAL POPULATION MORTALITY HAZARDS IN SURVIVAL EXTRAPOLATIONS

    Nov 1, 2019, 00:00 AM

  • Mental Health - Clinical Outcomes

    Nov 1, 2019, 00:00 AM

  • PMU40 NEWLY DIAGNOSED DEPRESSION AND DEPRESSION SEVERITY AMONG WOMEN WITH INCIDENT BREAST CANCER

    Nov 1, 2019, 00:00 AM

  • PMH32 THE ECONOMIC BURDEN OF ALCOHOL CONSUMPTION IN THE CZECH REPUBLIC

    Nov 1, 2019, 00:00 AM

  • PMS47 SIZING THE PATIENT POTENTIAL FOR DISEASE MODIFYING OSTEOARTHRITIS THERAPIES IN USA AND EU MARKETS

    Nov 1, 2019, 00:00 AM

  • PCN436 RESPONSIVENESS OF THE EQ-5D-5L AND EORTC QLU-C10D IN CANCER PATIENTS

    Nov 1, 2019, 00:00 AM

  • PSU18 THE COST-EFFECTIVENESS OF ENOXAPARIN IN THE PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING MAJOR SURGERY IN EGYPT

    Nov 1, 2019, 00:00 AM

  • PNS229 COMPARATIVE ANALYSIS OF TRANSPARENCY COMMITTEE OPINION CONCERNING THE ADDED MEDICAL BENEFIT OBTAINED BY DRUGS AVAILABLE THROUGH EARLY ACCESS PROGRAM VS THE OTHERS

    Nov 1, 2019, 00:00 AM

  • PCV145 ASSOCIATION BETWEEN NICORANDIL AND GASTROINTESTINAL ULCERS: A POPULATION-BASED STUDY

    Nov 1, 2019, 00:00 AM

  • PRO44 THE ECONOMIC IMPACT AND HEALTH-RELATED QUALITY OF LIFE OF SPINAL MUSCULAR ATROPHY (SMA). AN ANALYSIS ACROSS THREE EUROPEAN COUNTRIES

    Nov 1, 2019, 00:00 AM

  • PMU13 COST-EFFECTIVENESS ANALYSIS OF PCT-GUIDED ANTIBIOTIC STEWARDSHIP FOR HOSPITALIZED PATIENTS WITH SEPSIS OR LOWER RESPIRATORY TRACT INFECTIONS IN A US HOSPITAL

    Nov 1, 2019, 00:00 AM

  • PRO69 EPIDEMIOLOGICAL MODEL TO SUPPORT ORPHAN DESIGNATION DECISIONS: A DICE SIMULATION STUDY

    Nov 1, 2019, 00:00 AM

  • Adherence, Persistence and Compliance Studies

    Nov 1, 2019, 00:00 AM

  • PDB39 INSULIN PRICE FLUCTUATION IN THE USA BETWEEN JULY 2017 AND JULY 2019

    Nov 1, 2019, 00:00 AM

  • PRO45 NATIONAL BURDEN OF HEMOPHILIA A IN TURKEY

    Nov 1, 2019, 00:00 AM

  • PCN313 REAL-WORLD DATA ON THE USE OF ANTINEOPLASTIC PHARMACOTHERAPY REGIMENS AMONG PATIENTS WITH SKIN MELANOMA IN RUSSIA

    Nov 1, 2019, 00:00 AM

  • PCN383 COST-EFFECTIVENES ANALYSIS OF AVELUMAB AS SECOND-LINE TREATMENT FOR PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA IN RUSSIA

    Nov 1, 2019, 00:00 AM

  • PNS231 MANAGED ENTRY AGREEMENTS FOR PRESCRIPTION DRUGS IN SWEDEN

    Nov 1, 2019, 00:00 AM

  • PMH25 ASSOCIATION OF ADOLESCENT DEPRESSION WITH EARNINGS IN ADULTHOOD

    Nov 1, 2019, 00:00 AM

  • PMU11 MAIN WEAKNESSES AND PROBLEMATICS OF CYBERSECURITY IN MEDICAL DEVICES

    Nov 1, 2019, 00:00 AM

  • PND60 HEALTH CARE RESOURCE UTILIZATION AND DIRECT MEDICAL COSTS AMONG PATIENTS WITH INCIDENT MIGRAINE INITIATING TREATMENT - A COHORT STUDY USING THE CLINICAL PRACTICE RESEARCH DATALINK

    Nov 1, 2019, 00:00 AM

  • PCN206 NETUPITANT AND PALONOSETRON (NEPA), IS A COST-EFFECTIVE INTERVENTION FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN SINGAPORE

    Nov 1, 2019, 00:00 AM

  • PSY10 PRIMARY SJOGREN'S SYNDROME: A RETROSPECTIVE COHORT STUDY OF BURDEN OF ILLNESS IN SWEDEN

    Nov 1, 2019, 00:00 AM

  • PDB40 PREDICTIVE ANALYSIS OF COST AND CAPACITY EFFECTS OF THE DIGITALIZED SECONDARY CARE SERVICES FOR INSULIN-DEPENDENT DIABETES PATIENTS @ VIRTUAL HOSPITAL 2.0

    Nov 1, 2019, 00:00 AM

  • PSY2 SYSTEMIC LUPUS ERYTHEMATOSUS: A TARGETED LITERATURE REVIEW OF ECONOMIC BURDEN WORLDWIDE

    Nov 1, 2019, 00:00 AM

  • PBI65 ASSESSMENT OF WILLINGNESS TO PAY IN A RAPIDLY INCREASING BIOLOGICS MARKET FOR RESPIRATORY DISEASES

    Nov 1, 2019, 00:00 AM

  • PDB33 COST-EFFECTIVENESS OF THE PDM-PROVALUE STUDY PROGRAM IN INSULIN-TREATED PATIENTS WITH TYPE 2 DIABETES MELLITUS FROM THE GERMAN STATUTORY HEALTHCARE PERSPECTIVE

    Nov 1, 2019, 00:00 AM

  • PCN243 COST-MINIMIZATION OF VENETOCLAX WITH RITUXIMAB VERSUS IBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

    Nov 1, 2019, 00:00 AM

  • PSU35 COMPLICATIONS AND REIMBURSEMENT AMONG PATIENTS WITH HAMMERTOE SURGERY: A COMMERCIAL CLAIMS DATABASE STUDY WITH TWO-YEAR FOLLOW-UP

    Nov 1, 2019, 00:00 AM

  • PCN419 THE USE OF INDIVIDUAL PATIENT-LEVEL DATA (IPD) TO CONDUCT INDIRECT TREATMENT COMPARISONS (ITCS) IN SUBMISSIONS TO THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE)

    Nov 1, 2019, 00:00 AM

  • PMD24 ECONOMIC EVALUATION OF CENTRIFUGAL AND MEMBRANE THERAPEUTIC PLASMA EXCHANGE IN TAIWAN

    Nov 1, 2019, 00:00 AM

  • PNS215 IMPACT OF CONDITIONAL MARKETING AUTHORISATION AND ACCELERATED ASSESSMENT ON HEALTH TECHNOLOGY ASSESSMENT (HTA) OUTCOMES

    Nov 1, 2019, 00:00 AM

  • PBI45 UPTAKE OF BIOSIMILAR INFLIXIMAB: BUDGET SAVINGS OR MARKET EXPANSION ACROSS COUNTRIES?

    Nov 1, 2019, 00:00 AM

  • PCN414 INCLUSION OF SUBSEQUENT TREATMENTS WITH CURATIVE INTENT IN ADVANCED HEPATOCELLULAR CARCINOMA (AHCC) PARTITIONED SURVIVAL MODELS

    Nov 1, 2019, 00:00 AM

  • PNS145 THE MALTESE EXCEPTIONAL MEDICINAL TREATMENT ROUTE: A BYPASS TO HEALTHCARE?

    Nov 1, 2019, 00:00 AM

  • PGI24 IBD INTEGRATED MODEL OF CARE LEADS TO COST SAVINGS: A BUDGET IMPACT MODEL FOR A RUSSIAN REGION

    Nov 1, 2019, 00:00 AM

  • PSU11 ROBOTIC VS LAPAROSCOPIC RIGHT HEMICOLECTOMY: A COMPARATIVE STUDY OF CLINICAL OUTCOMES AND COSTS-EFFECTIVENESS

    Nov 1, 2019, 00:00 AM

  • PCN400 ONCOLOGY-RELATED HTA DECISIONS IN GERMANY, FRANCE, SPAIN AND THE UK: ASSESSMENT OF SIMILARITIES AND DIFFERENCES

    Nov 1, 2019, 00:00 AM

  • PDB49 THE RELATIONSHIP BETWEEN HBA1C REDUCTION AND COSTS: A COHORT STUDY OF PATIENTS WITH TYPE 2 DIABETES

    Nov 1, 2019, 00:00 AM

  • PCN366 TREATMENT LANDSCAPE AND KEY DRIVERS FOR HTA DECISIONS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER WITHOUT EGFR OR ALK ALTERATIONS

    Nov 1, 2019, 00:00 AM

  • PDG50 PHARMACEUTICAL PRICING POLICIES IN QATAR AND LEBANON: NARRATIVE REVIEW AND DOCUMENT ANALYSIS

    Nov 1, 2019, 00:00 AM

  • PRS69 TREATMENT OF COPD PATIENTS IN GERMANY AND THE NEED FOR THERAPY ESCALATION: A CLAIMS DATA ANALYSIS

    Nov 1, 2019, 00:00 AM

  • PCN203 HEALTH-CARE RESOURCE USE AND COSTS IN AML-PATIENTS UNDERGOING STEM CELL TRANSPLANTATION

    Nov 1, 2019, 00:00 AM

  • PRS73 POLLEN EXPOSURE AND ASTHMA-RELATED HEALTHCARE RESOURCE UTILIZATION IN CHILDREN WITH ASTHMA: AN ANALYSIS OF PATIENT-LEVEL CLAIMS AND LINKED WEATHER DATA

    Nov 1, 2019, 00:00 AM

  • PNS116 COMPARATIVE PRICING POLICY ANALYSIS BETWEEN DENMARK AND FRANCE.

    Nov 1, 2019, 00:00 AM

  • PRO105 A REVIEW OF SIX YEARS OF THE NICE HIGHLY SPECIALISED TECHNOLOGY (HST) PROGRAMME

    Nov 1, 2019, 00:00 AM

  • PNS58 ANALYSIS OF FINANCIAL STATUS AND DETERMINANTS WITH ALTMAN'S Z-SCORE MODEL: A PANEL DATA INVESTIGATION FROM TRADITIONAL CHINESE MEDICINE LISTED COMPANIES IN CHINA

    Nov 1, 2019, 00:00 AM

  • PND67 IDENTIFICATION AND CHARACTERIZATION OF HIGH DISEASE ACTIVITY RELAPSING REMITTING MULTIPLE SCLEROSIS ADULT PATIENTS BASED ON THE SNIIRAM DATABASE

    Nov 1, 2019, 00:00 AM

  • PRO76 ITALIAN 648/96 LAW APPLICATION BETWEEN JAN 2013 AND MAY 2019: FOCUS ON ORPHAN DRUGS

    Nov 1, 2019, 00:00 AM

  • PND80 HEALTHCARE UTILISATION AND PERCEIVED HEALTH NEEDS OF MULTIPLE SCLEROSIS PATIENTS IN GREECE: EVIDENCE FROM A QUALITATIVE STUDY

    Nov 1, 2019, 00:00 AM

  • PND125 PREGABALIN PRESCRIBING IN PRIVATE HEALTHCARE SETTINGS IN SOUTH AFRICA WITH SPECIFIC FOCUS ON DOSAGES

    Nov 1, 2019, 00:00 AM

  • PDB3 HETEROGENEITY IN RENAL COMPOSITE ENDPOINTS IN CARDIOVASCULAR OUTCOMES TRIALS IN TYPE 2 DIABETES (T2D)

    Nov 1, 2019, 00:00 AM

  • PND115 PATIENT REALITIES IN MIGRAINE. LITERATURE REVIEW ENHANCED BY SOCIAL MEDIA

    Nov 1, 2019, 00:00 AM

  • PNS169 PERSONAL MEDICAL HEALTH RECORDS REGULATION IN THE UNITED STATED, EUROPEAN UNION AND ISRAEL

    Nov 1, 2019, 00:00 AM

  • PND102 BURDEN OF COMORBID DEPRESSION AND ANXIETY ON MIGRAINE-SPECIFIC HEALTH-RELATED QUALITY OF LIFE IN ADULT MIGRAINE PATIENTS IN THE UNITED STATES

    Nov 1, 2019, 00:00 AM

  • PCN218 COST-EFFECTIVENESS OF APALUTAMIDE + ADT VERSUS ENZALUTAMIDE + ADT IN NON-METASTATIC CASTRATION RESISTANT PROSTATE CANCER IN GREECE

    Nov 1, 2019, 00:00 AM

  • PND33 THE CLINICAL AND ECONOMIC BURDEN OF OBSTRUCTIVE SLEEP APNEA IN ADULTS: A COST-OF-ILLNESS ANALYSIS

    Nov 1, 2019, 00:00 AM

  • PIH57 THE BLEEDING AND PELVIC DISCOMFORT SCALE: MEASURING PATIENT-REPORTED SYMPTOMS IN UTERINE FIBROIDS

    Nov 1, 2019, 00:00 AM

  • PCN444 DYNAMIC SURVIVAL MODELS FOR INCORPORATING EXTERNAL EVIDENCE WHEN EXTRAPOLATING OVERALL SURVIVAL: A CASE STUDY.

    Nov 1, 2019, 00:00 AM

  • PDG104 DECREASING NUMBER OF PRESCRIPTIONS AFTER THEY BECAME MANDATORY AND THEIR VALIDITY PERIOD WAS EXTENDED TO TWO YEARS: CASE FINLAND SINCE 2017

    Nov 1, 2019, 00:00 AM

  • PMU142 ASSESSING THE HUMAN AND ECONOMIC BURDEN OF SHORT STATURE: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00 AM

  • PCN296 OUT WITH THE OLD AND IN WITH THE NEW: THE EVOLUTION OF THE CANCER DRUGS FUND

    Nov 1, 2019, 00:00 AM

  • PMU70 FACTORS INFLUENCING THE SELECTION OF PRODUCTS FOR THE ACCELERATED ACCESS COLLABORATIVE'S RAPID UPTAKE PATHWAY

    Nov 1, 2019, 00:00 AM

  • PCN357 PREDICTOR OF A POSITIVE RECOMMENDATION IN NICE ONCOLOGY APPRAISALS

    Nov 1, 2019, 00:00 AM

  • PNS170 CHEAP OR TIMELY DRUG? PRACTICAL IMPACT OF EXTERNAL REFERENCE PRICING POLICY IN THE EUROPEAN UNION

    Nov 1, 2019, 00:00 AM

  • PMH27 SUCCESSFULLY TREATED PATIENTS WITH VORTIOXETINE VERSUS VENLAFAXINE: A SIMPLIFIED COST-EFFECTIVENESS ANALYSIS IN ASIAN PATIENTS WITH MAJOR DEPRESSIVE DISORDER

    Nov 1, 2019, 00:00 AM

  • PCN259 SKELETAL ADVERSE EVENTS ASSOCIATED WITH IMMUNE CHECKPOINT INHIBITORS: EMERGING TRENDS FROM THE US FOOD AND DRUG ADMINISTRATION ADVERSE EVENT REPORTING SYSTEM

    Nov 1, 2019, 00:00 AM

  • PDG98 A DISPROPORTIONALITY ANALYSIS OF SPONTANEOUS ADVERSE EVENT REPORTS FOR OSTEONECROSIS OF JAW ATTRIBUTED TO AROMATASE INHIBITORS IN FDA ADVERSE EVENTS REPORTING SYSTEM

    Nov 1, 2019, 00:00 AM

  • PUK2 A SYSTEMATIC REVIEW ASSESSING THE LONG-TERM EFFECTS OF MAINTAINING RAASI TREATMENT IN PATIENTS WITH CHRONIC KIDNEY DISEASE

    Nov 1, 2019, 00:00 AM

  • PCN318 CLINICAL AND TREATMENT CHARACTERISTICS OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN EUROPE

    Nov 1, 2019, 00:00 AM

  • PIN70 COST-EFFECTIVENESS OF SEASONAL VACCINATION WITH QUADRIVALENT INFLUENZA VACCINE IN PORTUGAL

    Nov 1, 2019, 00:00 AM

  • PCN509 REAL-WORLD EVIDENCE ON PATIENTS WITH RELAPSED/REFRACTORY FLT3 MUTATION-POSITIVE ACUTE MYELOID LEUKEMIA IN ITALY

    Nov 1, 2019, 00:00 AM

  • PUK25 THE EFFECTIVENESS OF A DIGITAL PELVIC FLOOR TRAINING PROGRAM IN THE TREATMENT OF URINARY INCONTINENCE - A REAL WORLD EVALUATION

    Nov 1, 2019, 00:00 AM

  • Treatment Patterns Guidelines Studies

    Nov 1, 2019, 00:00 AM

  • PND72 EVOLUTION OF THE CONSUMPTION OF ANTIEPILETEC DRUGS IN MOROCCO FROM 2004 TO 2016

    Nov 1, 2019, 00:00 AM

  • PCN37 THE BENEFIT OF ADJUVANT CHEMOTHERAPY FOR PATIENTS AGED 75 OR OLDER WITH STAGE III COLON CANCER

    Nov 1, 2019, 00:00 AM

  • PUK33 PATIENT INSIGHTS FOR COMPLEMENT 3 GLOMERULOPATHY (C3G) USING SOCIAL MEDIA LISTENING

    Nov 1, 2019, 00:00 AM

  • PIH54 HEALTH RELATED QUALITY OF LIFE OF PRE-ADOLESCENT DEAF CHILDREN WITH COCHLEAR IMPLANTS: A CONCEPTUAL DISEASE MODEL

    Nov 1, 2019, 00:00 AM

  • Respiratory-Related Disorders - Methodological Statistical Research

    Nov 1, 2019, 00:00 AM

  • PIN153 HEALTH OUTCOMES AND HEALTH SYSTEM COSTS ASSOCIATED WITH SEPSIS: A POPULATION-BASED, RETROSPECTIVE COHORT STUDY

    Nov 1, 2019, 00:00 AM

  • PNS264 AN ASSESSMENT OF THE RECOMMENDATIONS MADE BY NICE'S MEDICAL TECHNOLOGIES EVALUATION PROGRAMME, AND WHETHER THE RECOMMENDATIONS SUPPORT MTEP'S STATED AIMS.

    Nov 1, 2019, 00:00 AM

  • PCV124 REPORTING AND QUALITY OF PATIENT PREFERENCE STUDIES: A SYSTEMATIC LITERATURE REVIEW IN THE CARDIOVASCULAR DOMAIN

    Nov 1, 2019, 00:00 AM

  • Comparative Effectiveness or Efficacy Studies

    Nov 1, 2019, 00:00 AM

  • Systemic Disorders/Conditions - Organizational Practices

    Nov 1, 2019, 00:00 AM

  • Neurological Disorders - Medical Technologies

    Nov 1, 2019, 00:00 AM

  • Infectious Diseases - Economic Evaluation

    Nov 1, 2019, 00:00 AM

  • PRO17 A BUDGET IMPACT ANALYSIS OF ANTI-INHIBITOR COAGULANT COMPLEX USE IN PEDIATRIC HEMOPHILIA A PATIENTS WITH INHIBITORS ACROSS KINGDOM OF SAUDI ARABIA.

    Nov 1, 2019, 00:00 AM

  • PDB69 ECONOMIC BURDEN OF TYPE 2 DIABETES (T2D) IN EMERGING AND ESTABLISHED MARKETS: DATA FROM THE G15 REVIEW

    Nov 1, 2019, 00:00 AM

  • PMS11 A RETROSPECTIVE COHORT ANALYSIS OF THE BURDEN OF TOTAL KNEE ARTHROPLASTY IN JAPAN

    Nov 1, 2019, 00:00 AM

  • PRO152 CONFIRMATORY PSYCHOMETRIC VALIDATION OF THE WESTERN ONTARIO MCMASTER UNIVERSITIES OSTEOARTHRITIS INVENTORY (WOMAC) IN ADULT X-LINKED HYPOPHOSPHATEMIA (XLH)

    Nov 1, 2019, 00:00 AM

  • PCV27 AN ECONOMIC ANALYSIS OF ENDOVASCULAR ARTERIOVENOUS FISTULAS IN DIALYSIS PATIENTS: A U.S. PAYER AND PROVIDER PERSPECTIVE

    Nov 1, 2019, 00:00 AM

  • PCN454 A MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF ELOTUZUMAB/POMALIDOMIDE/DEXAMETHASONE (EPD) VERSUS PANOBINOSTAT/BORTEZOMIB/DEXAMETHASONE (PANO-VD) AND DARATUMUMAB MONOTHERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

    Nov 1, 2019, 00:00 AM

  • PDG55 RISK SHARING AGREEMENT ON PRESCRIPTION DRUGS: 5 YEARS EXPERIENCE OF THE KOREA NATIONAL HEALTH INSURANCE

    Nov 1, 2019, 00:00 AM

  • PCV7 ESTIMATION THE PHYSICAL ACTIVITY OF HEART FAILURE PATIENTS BASED ON TELEMETRY DATA

    Nov 1, 2019, 00:00 AM

  • PIN105 DESCRIPTION OF PATIENTS HOSPITALIZED WITH MENINGOCOCCAL INFECTIONS IN FRANCE: AN ANALYSIS OF THE NATIONAL HEALTHCARE CLAIM(SNIIR-AM) DATABASE

    Nov 1, 2019, 00:00 AM

  • PNS150 CONDITIONAL MARKETING AUTHORISATION FOR NOVEL TREATMENTS: A LANDSCAPE ASSESSMENT OF EXPEDITED PATHWAYS OUTSIDE US AND EU

    Nov 1, 2019, 00:00 AM

  • PIN13 FIRST EMA-EUNETHTA PARALLEL CONSULTATION FOR VACCINES

    Nov 1, 2019, 00:00 AM

  • PCN149 COST-EFFECTIVENESS ANALYSIS OF DABRAFENIB+TRAMETINIB VERSUS WATCHFUL WAITING IN THE ADJUVANT TREATMENT OF PATIENTS WITH RESECTED BRAF V600 POSITIVE STAGE III MELANOMA : A FRENCH PERSPECTIVE

    Nov 1, 2019, 00:00 AM

  • Alternative Medicine Statistical Research

    Nov 1, 2019, 00:00 AM

  • PDB38 COST OF ANTI-DIABETIC MEDICATIONS AMONG TYPE II DIABETES MELLITUS PATIENTS: A CROSS-SECTIONAL STUDY IN SOUTH INDIA

    Nov 1, 2019, 00:00 AM

  • Surgery - Methodological Statistical Research

    Nov 1, 2019, 00:00 AM

  • PMU105 ACCEPTANCE OF EVIDENCE TRANSFER FROM ADULTS TO CHILDREN IN THE CONTEXT OF BENEFIT ASSESSMENT IN GERMANY, FRANCE, AND UK

    Nov 1, 2019, 00:00 AM

  • PMU152 SWITCHING AMONG BIOLOGIC THERAPIES IN PATIENTS WITH RHEUMATOID ARTHRITIS: A CROSS-SECTIONAL STUDY

    Nov 1, 2019, 00:00 AM

  • PND36 10-YEAR COST-EFFECTIVENESS ANALYSES OF FREMANEZUMAB COMPARED TO NO TREATMENT AS A PREVENTIVE TREATMENT IN CHRONIC AND EPISODIC MIGRAINE FOR PATIENTS WITH INADEQUATE RESPONSE TO PRIOR PREVENTIVE TREATMENTS

    Nov 1, 2019, 00:00 AM

  • PDG89 ADVANCED THERAPY MEDICINAL PRODUCT (ATMP) MARKET ACCESS - A CONTINUING CHALLENGE

    Nov 1, 2019, 00:00 AM

  • PNS244 PAN-EU CLINICAL HTA – A NON-UNIFORM IMPACT?

    Nov 1, 2019, 00:00 AM

  • PMS12 PATIENTS PRESCRIBED WITH OPIOID TREATMENT IN PRIMARY CARE PRACTICES: A POPULATION-BASED STUDY IN ITALY

    Nov 1, 2019, 00:00 AM

  • PCN67 COST-EFFECTIVENESS ANALYSIS OF DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY IN PORTUGAL

    Nov 1, 2019, 00:00 AM

  • Systemic Disorders/Conditions - Health Technology Assessment

    Nov 1, 2019, 00:00 AM

  • Drugs Generics - Organizational Practices

    Nov 1, 2019, 00:00 AM

  • PSY54 WEB SURVEY AND FOCUS GROUPS EXPLORING KNOWLEDGE, NEEDS AND EXPECTATIONS AMONG SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS: PRELIMINARY RESULTS

    Nov 1, 2019, 00:00 AM

  • PMU62 ASSESSING WHETHER PRODUCTS NEED TO BE COST-SAVING IN ORDER TO GAIN ACCELERATED ACCESS COLLABORATIVE RAPID UPTAKE STATUS IN NHS ENGLAND

    Nov 1, 2019, 00:00 AM

  • PCN264 ESTIMATING THE BURDEN OF SALIVARY GLAND CANCER IN NORDIC COUNTRIES: A PREDICTIVE ANALYSIS USING TIME SERIES ANALYSIS METHODS

    Nov 1, 2019, 00:00 AM

  • PDB82 THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE AND LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): COUNTRY-SPECIFIC BASELINE CHARACTERISTICS

    Nov 1, 2019, 00:00 AM

  • PRS22 THE COST EFFECTIVENESS OF DORNASE ALFA VERSUS INHALED TOBRAMYCIN IN THE MANAGEMENT OF PATIENTS WITH CYSTIC FIBROSIS

    Nov 1, 2019, 00:00 AM

  • PNS112 PHARMACIST’S PRIVILEGE IN SAUDI ARABIA: PHARMACIST PRESCRIBING AND THERAPEUTIC INTERCHANGE

    Nov 1, 2019, 00:00 AM

  • PDG76 IN VITRO DATA AS COMPLEMENTARY EVIDENCE SOURCE FOR THE ASSESSMENT OF ANTIBIOTICS IN THE GERMAN BENEFIT ASSESSMENT?

    Nov 1, 2019, 00:00 AM

  • PCN355 DO PAYER AND PRESCRIBER ENDPOINT PREFERENCES ALIGN?: IMMUNE CHECKPOINT INHIBITORS IN NON-SMALL CELL LUNG CANCER

    Nov 1, 2019, 00:00 AM

  • PMS38 COST-EFFECTIVENESS ANALYSIS OF TOCILIZUMAB SC IN COMPARISON WITH ANAKINRA IN SYSTEMIC IDIOPATHIC JUVENILE ARTHRITIS (SJIA) TREATMENT IN TURKEY

    Nov 1, 2019, 00:00 AM

  • PMD15 COST EFFECTIVENESS ANALYSIS OF STANDARD AND PREMIUM INTRAOCULAR LENSES IMPLEMENTED IN THE TREATMENT OF CATARACT UNDER DIFFERENT INSURANCE SCHEMES IN EGYPT

    Nov 1, 2019, 00:00 AM

  • PCN494 POTENTIAL USE OF ARTIFICIAL INTELLIGENCE TO ANALYZE DATA EXTRACTED FROM ELECTRONIC HEALTH RECORDS FOR DECISION ANALYTIC MODELS

    Nov 1, 2019, 00:00 AM

  • PCV16 MULTIPLE STATISTICAL APPROACHES IN COMPARATIVE EFFECTIVENESS RESEARCH (CER): THE EXAMPLE OF NAXOS, A LARGE FRENCH CER

    Nov 1, 2019, 00:00 AM

  • PNS397 PATIENTS' PERCEPTION OF THE QUALITY OF CONSULTATIONS MODELLED BY PATIENT-REPORTED EXPERIENCE AND HEALTH-RELATED QUALITY OF LIFE MEASURES

    Nov 1, 2019, 00:00 AM

  • PIN86 CLINICAL AND ECONOMIC OUTCOMES ASSOCIATED WITH VARYING COVERAGE OF VARICELLA VACCINATION STRATEGIES IN SWITZERLAND

    Nov 1, 2019, 00:00 AM

  • PCN364 REIMBURSEMENT OF CAR-T CELL THERAPY IN THE UK, A STEP TOWARDS MORE PERSONALISED CANCER TREATMENT

    Nov 1, 2019, 00:00 AM

  • PND55 ECONOMIC EVALUATION OF ENDOSCOPIC THIRD VENTRICULOSTOMY COMPARED TO SHUNTING IN PEDIATRIC PATIENTS WITH HYDROCEPHALUS IN UZBEKISTAN

    Nov 1, 2019, 00:00 AM

  • Mental Health - Conceptual Papers (CP)

    Nov 1, 2019, 00:00 AM

  • PRO26 THE NICE APPRAISAL OF BUROSUMAB FOR THE TREATMENT OF XLH: EVALUATING THE LIFELONG OUTCOMES AND COST-EFFECTIVENESS OF CORRECTING DEFORMITY WHEN TREATING CHILDREN AND ADOLESCENTS WITH A GROWING SKELETON

    Nov 1, 2019, 00:00 AM

  • PCN458 ATTITUDE TOWARDS PARTICIPATION ON BREAST CANCER SCREENING AND THE ASSESSMENT OF INFLUENCING FACTORS AMONG 45-65 YEARS OLD WOMEN

    Nov 1, 2019, 00:00 AM

  • PNS148 VALUE-BASED PROCUREMENT: UNDERSTANDING HOW PAYERS APPROACH AND IMPLEMENT CONTRACTING AND PROCUREMENT OF NOVEL TREATMENTS BASED ON THEIR VALUE

    Nov 1, 2019, 00:00 AM

  • PCN118 DIRECT MEDICAL COSTS OF THE TREATMENT OF RECTAL CANCER: A REVIEW AND SYNTHESIS OF THE PUBLISHED EVIDENCE

    Nov 1, 2019, 00:00 AM

  • PIN145 PATIENT PREFERENCES TOWARDS DRUG TREATMENT OF CHRONIC HEPATITIS B - A DISCRETE CHOICE EXPERIMENT IN GERMANY

    Nov 1, 2019, 00:00 AM

  • PNS250 CADTH PARALLEL SCIENTIFIC ADVICE PROGRAMS WITH NICE AND HEALTH CANADA

    Nov 1, 2019, 00:00 AM

  • PCN371 A REVIEW OF SWEDISH HEALTH TECHNOLOGY ASSESSMENTS BASED ON INDIRECT COMPARISONS OF HOSPITAL DRUGS IN ONCOLOGY

    Nov 1, 2019, 00:00 AM

  • PUK10 BUDGET IMPACT ANALYSIS OF DEGARELIX FOR THE TREATMENT OF PROSTATE CANCER IN CHINA

    Nov 1, 2019, 00:00 AM

  • PCN350 CLINICAL AND ECONOMIC ASSESSMENT OF THE IMPORTANCE OF SUPPORTIVE THERAPY IN ONCOLOGY

    Nov 1, 2019, 00:00 AM

  • PCN434 THE EFFECT MODIFICATION PROBLEM: USING STRATIFIED MATCHING ADJUSTED INDIRECT COMPARISON TO EVADE MISLEADING INTERPRETATIONS OF THE TREATMENT EFFECT

    Nov 1, 2019, 00:00 AM

  • PMU85 LESSONS FOR BREAKING NEW GROUND WITH FIRST-IN-CLASS THERAPIES

    Nov 1, 2019, 00:00 AM

  • PIN136 MODELLING CD4 TRANSITIONS IN HIV PATIENTS: VALIDATING A MARKOV MODEL BASED APPROACH

    Nov 1, 2019, 00:00 AM

  • PRO9 A SYSTEMATIC REVIEW OF THE CLINICAL BURDEN OF IDIOPATHIC MULTICENTRIC CASTLEMAN'S DISEASE

    Nov 1, 2019, 00:00 AM

  • PRO123 DEVELOPING AN EVIDENCE GENERATION PLAN FOR THE VALUE STORY OF AN ORPHAN DRUG

    Nov 1, 2019, 00:00 AM

  • PCN200 REAL-WORLD HEALTHCARE RESOURCE UTILIZATION IN PATIENTS SUFFERING FROM MALIGNANT MELANOMA, A FINNISH REGISTRY STUDY

    Nov 1, 2019, 00:00 AM

  • PDB44 COST-EFFECTIVENESS ANALYSIS OF INTRAVITREAL AFLIBERCEPT VERSUS LASER PHOTOCOAGULATION AND RANIBIZUMAB IN THE TREATMENT OF VISUAL IMPAIRMENT DUE TO DIABETIC MACULAR EDEMA IN CHINA

    Nov 1, 2019, 00:00 AM

  • PCN305 FUNDING TRENDS FOR IN-HOSPITAL DRUGS: GERMAN NUB ANALYSIS

    Nov 1, 2019, 00:00 AM

  • PCN238 IS POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE-RITUXIMAB COST-EFFECTIVE FOR PATIENTS IN THE UNITED STATES WITH TRANSPLANT-INELIGIBLE RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA?

    Nov 1, 2019, 00:00 AM

  • PCN410 USE OF EXTERNAL INFORMATION FROM HISTORICAL TRIAL DATA TO IMPROVE SURVIVAL ESTIMATIONS ON IMMATURE SURVIVAL DATA IN MULTIPLE MYELOMA (MM)

    Nov 1, 2019, 00:00 AM

  • PND11 IMPACT OF A COMMUNITY PHARMACY-BASED INFORMATION PROTOCOL ON MULTIPLE SCLEROSIS PATIENTS' ADHERENCE TO THEIR ORAL TREATMENT WITH DIMETHYL FUMARATE: TECPHIE, A RANDOMIZED STUDY VS USUAL PRACTICE (INTERIM RESULTS)

    Nov 1, 2019, 00:00 AM

  • PR2 FATIGUE: ITS USE ACROSS TRIALS FOR MULTIPLE CONDITIONS: REGULATORY SUCCESS

    Nov 1, 2019, 00:00 AM

  • PCN336 PARALLEL SCIENTIFIC ADVICE FROM NICE AND CADTH: WOULD ONE SUBMISSION FIT ALL?

    Nov 1, 2019, 00:00 AM

  • PMH34 THE ECONOMIC BURDEN OF SCHIZOPHRENIA: A REAL-WORLD DATA ANALYSIS IN ITALY

    Nov 1, 2019, 00:00 AM

  • PMS23 NATIONWIDE ANNUAL HEALTH INSURANCE TREATMENT COST OF INJURIES TO THE ANKLE AND FOOT IN HUNGARY: COST OF ILLNESS STUDY BASED ON REAL WORLD DATA

    Nov 1, 2019, 00:00 AM

  • PNS126 NEW DRUG BUDGET AND REIMBURSEMENT POLICY IN TAIWAN

    Nov 1, 2019, 00:00 AM

  • PSS20 CONFIRMATION OF THE MEASUREMENT PROPERTIES OF THE NATIONAL EYE INSTITUTE VISUAL FUNCTIONING QUESTIONNAIRE 28 ITEM RASCH-BASED SCORING IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

    Nov 1, 2019, 00:00 AM

  • PSY40 ASSESSING THE QUALITY AND COHERENCE OF NETWORK META-ANALYSES OF BIOLOGICS IN PLAQUE PSORIASIS: WHAT DOES ALL THIS EVIDENCE SYNTHESIS TELL US?

    Nov 1, 2019, 00:00 AM

  • PNS336 NETWORK META-ANALYSIS (NMA) WITH TIME-VARYING HAZARD: A COMPARATIVE ANALYSIS OF SURVIVAL OUTCOMES

    Nov 1, 2019, 00:00 AM

  • PDB32 WOULD A COHORT-LEVEL APPROACH TO COST-EFFECTIVENESS MODELLING HAVE LED TO A DIFFERENT DECISION IN AN IMPORTANT NICE APPRAISAL FOR OBESITY PATIENTS?

    Nov 1, 2019, 00:00 AM

  • PCN47 REAL WORLD EVIDENCE OF DARATUMUMAB IN MULTIPLE MYELOMA

    Nov 1, 2019, 00:00 AM

  • PCN184 ECONOMIC EVALUATION OF CHECKPOINT INHIBITORS FOR THE TREATMENT OF ADVANCED MELANOMA IN THE IRISH HEALTHCARE SETTING

    Nov 1, 2019, 00:00 AM

  • PCN281 IDENTIFYING THE KEY CHALLENGES IN EVALUATION AND PRICING OF ONCOLOGY COMBINATION THERAPIES AND FUTURE POLICY CHANGES USING A WEB-BASED PORTAL TO ENGAGE PAYERS

    Nov 1, 2019, 00:00 AM

  • PCN412 COMPARING THE LONG-TERM SURVIVAL METHODOLOGIES IN PHARMACOECONOMIC MODELS OR GLIOBLASTOMA: WHICH BEST REFLECT REAL-WORLD OUTCOMES?

    Nov 1, 2019, 00:00 AM

  • PCN480 RELEVANCE OF SELECTED PATIENT-REPORTED OUTCOME (PRO) MEASURES IN EPSTEIN-BARR VIRUS ASSOCIATED (EBV+) POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE (PTLD) PATIENTS

    Nov 1, 2019, 00:00 AM

  • PRO11 FACTORS ASSOCIATED WITH BLEEDING EXPERIENCE IN HEMOPHILIA A PATIENTS IN SOUTH KOREA

    Nov 1, 2019, 00:00 AM

  • PCV105 A SCOPING REVIEW OF INTERNATIONAL MODELS OF ADULT SPECIALIST CARDIAC NETWORKS

    Nov 1, 2019, 00:00 AM

  • PIN94 HUMAN PAPILLOMAVIRUS (HPV) VACCINE COVERAGE RATES (VCR) IN FRANCE: A FRENCH CLAIMS DATA STUDY

    Nov 1, 2019, 00:00 AM

  • PDB106 DOES MOBILE HEALTH LIVE UP TO EXPECTATIONS? EXPLORING REAL-WORLD EXPERIENCES IN PATIENTS WITH DIABETES

    Nov 1, 2019, 00:00 AM

  • PSS4 COST-EFFECTIVENESS ANALYSIS OF CONBERCEPT VERSUS RANIBIZUMAB FOR THE TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION (CNV) IN CHINA

    Nov 1, 2019, 00:00 AM

  • PIN113 EU MARKET ACCESS PATHWAYS FOR VACCINES: DEFINITION OF COUNTRY ARCHETYPES USING MATHEMATICAL CLUSTERING

    Nov 1, 2019, 00:00 AM

  • PCV86 ASSOCIATION OF ADHERENCE AND TREATMENT INTENSITY OF LIPID-LOWERING THERAPY WITH CARDIOVASCULAR OUTCOMES AND ALL-CAUSE MORTALITY IN POST-MI PATIENTS IN GERMANY.

    Nov 1, 2019, 00:00 AM

  • PSU44 MANAGEMENT OF PERIPROCEDURAL THROMBOTIC AND BLEEDING EVENTS IN PERCUTANEOUS CORONARY INTERVENTIONS IN EUROPE: PILOT SURVEY OF TREATMENT STRATEGIES AND HOSPITAL RESOURCES USE

    Nov 1, 2019, 00:00 AM

  • PRS41 IDENTIFICATION OF POTENTIALLY UNDIAGNOSED PATIENTS WITH NON-TUBERCULOUS MYCOBACTERIAL LUNG DISEASE USING MACHINE LEARNING APPLIED TO PRIMARY CARE DATA IN UK

    Nov 1, 2019, 00:00 AM

  • PND133 IMPACT OF CLINICAL COMPLICATIONS ON ECONOMIC BURDEN IN NEWLY DIAGNOSED PARKINSON POPULATION USING A US CLAIM DATABASE

    Nov 1, 2019, 00:00 AM

  • PDG14 COST-UTILITY OF DALBAVANCIN VERSUS STANDARD OF CARE (SOC) IN PATIENTS WITH ABSSSI IN ITALY

    Nov 1, 2019, 00:00 AM

  • PRS67 GENDER DIFFERENCES IN ASTHMA PERCEPTION AND IMPACT ON QUALITY OF LIFE: A POST-HOC ANALYSIS OF THE PROXIMA OBSERVATIONAL STUDY

    Nov 1, 2019, 00:00 AM

  • PGI51 PSYCHOMETRIC EVALUATION OF NASH-CHECK, A PATIENT-REPORTED OUTCOME MEASURE FOR NONALCOHOLIC STEATOHEPATITIS

    Nov 1, 2019, 00:00 AM

  • PNS97 GEOGRAPHIC DIFFERENCES IN IRISH HEALTH STATUS

    Nov 1, 2019, 00:00 AM

  • PCN22 BURDEN OF BRAIN METASTASES (BM) IN ALK+ NON-SMALL CELL LUNG CANCER (ALK+ NSCLC) TREATED WITH FIRST-LINE ALK INHIBITORS: RESULTS OF A SYSTEMATIC LITERATURE REVIEW (SLR)

    Nov 1, 2019, 00:00 AM

  • PMD8 ESTIMATING THE POTENTIAL CASES OF BLINDNESS AND COSTS AVOIDED AND IN REALLOCATING HEALTHCARE RESOURCE UTILIZATION FROM TREATING POSTERIOR CAPSULAR OPACIFICATION TO NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

    Nov 1, 2019, 00:00 AM

  • PDB26 THE BURDEN OF SEVERE HYPOPARATHYROIDISM IN GERMANY - A CLAIMS DATABASE ANALYSIS

    Nov 1, 2019, 00:00 AM

  • PIN57 ECONOMIC EVALUATION OF AN ELECTRONIC HEALTH RECORD ALERT BY AGE IN PRIMARY CARE FOR THE DETECTION OF PATIENTS WITH CHRONIC HEPATITIS C

    Nov 1, 2019, 00:00 AM

  • PND50 ECONOMIC BURDEN OF ALZHEIMER'S DISEASE DEMENTIA IN JAPAN

    Nov 1, 2019, 00:00 AM

  • PMD60 AN INNOVATIVE REUSABLE ELECTRONIC INJECTION DEVICE FOR CERTOLIZUMAB PEGOL: RESULTS FROM A PILOT MARKET RESEARCH STUDY EXAMINING PATIENT PREFERENCE AND SATISFACTION

    Nov 1, 2019, 00:00 AM

  • PCN469 DISEASE SPECIFIC PATIENT-REPORTED OUTCOME (PRO) INSTRUMENTS FOR HEMATOLOGIC MALIGNANCIES (HM)

    Nov 1, 2019, 00:00 AM

  • PNS332 DEALING WITH MISSING DATA IN TRIAL-BASED ECONOMIC EVALUATIONS: A METHODOLOGICAL SCOPING REVIEW

    Nov 1, 2019, 00:00 AM

  • PNS197 WAITING TIMES FOR HEALTH CARE SERVICES IN HUNGARY - RESULTS OF A REPRESENTATIVE POPULATION SURVEY

    Nov 1, 2019, 00:00 AM

  • PCN340 FAST CHANGING APPROPRIATE COMPARATORS IN GERMAN AMNOG BENEFIT ASSESSMENTS IN MULTIPLE MYELOMA

    Nov 1, 2019, 00:00 AM

  • PDG75 TRENDS IN THE USE OF PATIENT ACCESS SCHEMES AND COMMERCIAL ACCESS ARRANGEMENTS IN HEALTH TECHNOLOGY ASSESSMENTS (HTA) BY THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE)

    Nov 1, 2019, 00:00 AM

  • PDB129 PRIMARY AND SECONDARY HEALTHCARE RESOURCE USE AND ASSOCIATED COSTS IN PEOPLE WITH HEPATIC ENCEPHALOPATHY IN ENGLAND

    Nov 1, 2019, 00:00 AM

  • PNS384 HEALTH-RELATED QUALITY OF LIFE (HRQOL) MEASURED BY PROMIS PREFERENCE SCORE (PROPR) IN THE GENERAL POPULATION OF THE UNITED KINGDOM, FRANCE, AND GERMANY

    Nov 1, 2019, 00:00 AM

  • PNS3 COMPARISON OF FIVE METHODS FOR DOWNLOADING CONFERENCE ABSTRACTS: A CASE STUDY

    Nov 1, 2019, 00:00 AM

  • PCN344 ADDITION OF PERTUZUMAB TO TRASTUZUMAB-BASED ADJUVANT THERAPY IN HIGH-RISK HER2-POSITIVE EARLY BREAST CANCER: A GRADE-BASED ANALYSIS FROM THE PHASE III APHINITY TRIAL

    Nov 1, 2019, 00:00 AM

  • PNS115 BARRIERS TO TRANSPARENCY IMPROVEMENT OF HOSPITALS PERFORMANCE: A QUALITATIVE STUDY IN IRAN

    Nov 1, 2019, 00:00 AM

  • PMU34 COMPARATIVE ANALYSIS OF DISABILITY ADJUSTED LIFE YEARS FROM ADVERSE EFFECTS OF MEDICAL TREATMENT IN UKRAINE AND OTHER COUNTRIES

    Nov 1, 2019, 00:00 AM

  • PGI26 A BUDGET IMPACT ANALYSIS OF RIFAXIMIN FOR TREATMENT OF HEPATIC ENCEPHALOPATHY IN TERTIARY HOSPITAL,RIYADH, SAUDI ARABIA

    Nov 1, 2019, 00:00 AM

  • AI4 GENERAL PAIRWISE COMPARISONS TO SUPPORT QUANTITATIVE MULTIPLE CRITERIA DECISION ANALYSIS

    Nov 1, 2019, 00:00 AM

  • PMU22 BROADER ECONOMIC BURDEN OF SMOKING ATTRIBUTABLE DISEASES IN GREECE

    Nov 1, 2019, 00:00 AM

  • PIT15 INTRAMEDULLARY NAILING OF HUMERAL FRACTURES: PATIENT CHARACTERISTICS ASSOCIATED WITH POSTOPERATIVE COMPLICATIONS

    Nov 1, 2019, 00:00 AM

  • PMU84 DRUG DECISION-MAKING PATHWAYS IN ENGLAND: CURRENT PROCESSES AND THE POTENTIAL IMPACT OF NICE CHANGES

    Nov 1, 2019, 00:00 AM

  • PCV81 CURRENT TRENDS IN LIPID LOWERING THERAPY USE IN GERMANY

    Nov 1, 2019, 00:00 AM

  • PNS204 THE RELEVANCE OF REAL WORLD EVIDENCE STUDIES IN THE GERMAN BENEFIT ASSESSMENT (AMNOG) PROCESS

    Nov 1, 2019, 00:00 AM

  • PCN278 EXPLORING PRE AND POST AGENZIA ITALIANA DEL FARMACO (AIFA) REIMBURSED ACCESS TO IMMUNOTHERAPY FOR THE TREATMENT OF SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)

    Nov 1, 2019, 00:00 AM

  • PMH64 PHARMACOTHERAPY COST AND PRESCRIBING PRACTICE FOR PSYCHOTIC DISORDERS IN BULGARIA

    Nov 1, 2019, 00:00 AM

  • PCN75 EPIDEMIOLOGY, MORTALITY AND STANDARD OF CARE IN ADVANCED BREAST CANCER - A MULTIPLE COUNTRY ANALYSIS

    Nov 1, 2019, 00:00 AM

  • PCN394 DETERMINANTS OF MANAGED ENTRY AGREEMENTS IN THE CONTEXT OF HTA; EMPIRICAL EVIDENCE FROM ONCOLOGY MEDICINES IN FOUR COUNTRIES.

    Nov 1, 2019, 00:00 AM

  • Biologics/Biosimilars/Regenerative Medicine - Clinical Outcomes

    Nov 1, 2019, 00:00 AM

  • PRO97 VALUE ASSESSMENT FRAMEWORKS FOR ORPHAN DRUGS: A COMPARATIVE ANALYSIS ACROSS EUROPEAN JURISDICTIONS

    Nov 1, 2019, 00:00 AM

  • PCN173 ACCOUNTING FOR TIME-DEPENDENT HEALTH STATE MEMBERSHIP IN BUDGET IMPACT ANALYSIS - CASE STUDY IN ONCOLOGY

    Nov 1, 2019, 00:00 AM

  • PIN35 GLOBAL ANNUAL COSTS OF PEOPLE LIVING WITH HIV IN FRANCE IN 2013 FROM A NATIONAL INSURANCE CLAIMS DATABASE (SNIIRAM)

    Nov 1, 2019, 00:00 AM

  • PMD3 RETROSPECTIVE ANALYSIS OF OXIDIZED ZIRCONIUM BEARING SURFACE IN HIP REPLACEMENT 90-DAY EPISODE CLAIMS

    Nov 1, 2019, 00:00 AM

  • PND130 TREATMENT PATTERNS, HEALTH RESOURCES CONSUMPTION AND COSTS OF PATIENTS WITH MIGRAINE IN AN ITALIAN REAL-WORLD SETTING

    Nov 1, 2019, 00:00 AM

  • PBI31 COST-EFFECTIVENESS COMPARISON OF RISANKIZUMAB AND USTEKINUMAB FOR THE TREATMENT OF SEVERE PSORIASIS

    Nov 1, 2019, 00:00 AM

  • PND75 VALIDATION OF AN ALGORITHM IDENTIFYING RELAPSES IN MULTIPLE SCLEROSIS USING THE FRENCH NATIONWIDE CLAIMS DATABASE

    Nov 1, 2019, 00:00 AM

  • PCN423 MEASURING FATIGUE SYMPTOMS AND IMPACTS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): EVALUATING DIMENSIONALITY OF THE FACIT-FATIGUE

    Nov 1, 2019, 00:00 AM

  • PIN2 EFFECTIVENESS AND SAFETY OF DIRECT-ACTING ANTIVIRALS FOR HEPATITIS C VIRUS INFECTED PATIENTS AFTER LIVER TRANSPLANTATION. RESULTS IN REAL CLINICAL PRACTICE.

    Nov 1, 2019, 00:00 AM

  • PND118 PATIENTS WITH CHRONIC PAIN DISORDERS: PREFERENCE OF EPRO SCREEN DISPLAY AND FEATURES

    Nov 1, 2019, 00:00 AM

  • PDG109 REPLACING BRANDED ANTINEOPLASTIC DRUGS WITH GENERICS OR BIOSIMILARS: FORCAST OF BUDGET SAVINGS FOR THE PERSPECTIVE PERIOD

    Nov 1, 2019, 00:00 AM

  • PDG54 INTERNATIONAL COMPARISON OF ORPHAN DRUG POLICY EFFECT ON ORPHAN DRUG EXPENDITURE

    Nov 1, 2019, 00:00 AM

  • PIT2 PATTERNS OF OPIOID USE FOLLOWING FRACTURE BASED ON TIME BETWEEN PRESCRIPTION ORDER AND PATIENT FILL

    Nov 1, 2019, 00:00 AM

  • PSY15 COMPARISONS OF COSTS RELATED TO THE INITIATION OF TAPENTADOL OR OXYCODONE TREATMENT IN SPANISH PATIENTS SUFFERING FROM SEVERE NON-MALIGNANT PAIN

    Nov 1, 2019, 00:00 AM

  • PCN438 ECONOMIC EVALUATION METHODS IN ONCOLOGY: ONWARDS AND UPWARDS

    Nov 1, 2019, 00:00 AM

  • PDB56 ECONOMIC IMPACT OF TYPE 2 DIABETES AND DIABETES-ASSOCIATED COMPLICATIONS: A LARGE CLAIMS-BASED STUDY

    Nov 1, 2019, 00:00 AM

  • PCV14 COMPARATIVE EFFECTIVENESS AND SAFETY OF ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION: A PROPENSITY SCORE-MATCHED COHORT STUDY

    Nov 1, 2019, 00:00 AM

  • PMU91 CURRENT TREND OF UTILITY VALUES IN NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) TECHNOLOGY APPRAISAL GUIDANCE

    Nov 1, 2019, 00:00 AM

  • PCN127 NUMBER NEEDED TO TREAT (NNT) AND COST OF PREVENTING AN EVENT (COPE) COMPARISON BETWEEN THE TRIPLETS DRD AND KRD FOR RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA IN THE BRAZILIAN PRIVATE SYSTEM

    Nov 1, 2019, 00:00 AM

  • PNS143 PRIORITIZATION OF DRUGS FOR REIMBURSEMENT IN THE MALTESE HEALTH SYSTEM.

    Nov 1, 2019, 00:00 AM

  • PCN176 COST-EFFECTIVENESS OF SECOND-LINE NILOTINIB VERSUS DASATINIB FOR THE TREATMENT OF PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA-CHRONIC PHASE (PH+ CML-CP) IN ITALY

    Nov 1, 2019, 00:00 AM

  • PGI37 REDUCTION IN CO-THERAPY COSTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH BIOLOGICAL DRUGS

    Nov 1, 2019, 00:00 AM

  • PRO63 THE NATURAL HISTORY OF DUCHENNE MUSCULAR DYSTROPHY IN THE CORTICOSTEROID ERA: A SYSTEMATIC REVIEW OF STUDIES FROM CANADA AND THE US

    Nov 1, 2019, 00:00 AM

  • PNS11 EARLY HEALTH ECONOMIC MODELLING AS A TOOL TO GUIDE STRATEGIC CLINICAL DEVELOPMENT AND IN-LICENSING DECISIONS

    Nov 1, 2019, 00:00 AM

  • Musculoskeletal Disorders - Medical Technologies

    Nov 1, 2019, 00:00 AM

  • PNS178 PRIVATE HEALTH INSURANCE PERCEPTION OF THEIR ROLE AFTERWARD UNIVERSAL HEALTH INSURANCE IN EGYPT

    Nov 1, 2019, 00:00 AM

  • PRO64 MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA (MF-CTCL) EPIDEMIOLOGY AND TREATMENT PATHWAYS IN FRANCE AND SPAIN: NEW INSIGHTS FOR AN ACCURATE DESCRIPTION

    Nov 1, 2019, 00:00 AM

  • PNS73 WHAT IS THE VALUE FOR A QALY IN FRANCE?

    Nov 1, 2019, 00:00 AM

  • PCN18 CLINICAL BENEFITS OF REHABILITATION IN PATIENTS WITH ADVANCED CANCER IN KOREA

    Nov 1, 2019, 00:00 AM

  • PMU39 CERVICAL CANCER PREVENTION THROUGH HUMAN PAPILLOMAVIRUS (HPV) VACCINATION: A CASE STUDY IN ETHIOPIA

    Nov 1, 2019, 00:00 AM

  • PCN510 HEALTHCARE RESOURCE UTILISATION (HCRU) ASSOCIATED WITH TRANSCATHETER ARTERIAL CHEMOEMBOLISATION (TACE) TREATMENT IN INTERMEDIATE STAGE HEPATOCELLULAR CARCINOMA (HCC) PATIENTS IN EUROPE

    Nov 1, 2019, 00:00 AM

  • PNS289 EVALUATION OF THE SAFETY AND EFFICACY OF AI FOR DETECTION OF CHRONIC NON-COMMUNICABLE DISEASES IN REMOTE AREAS

    Nov 1, 2019, 00:00 AM

  • PDB9 SERUM GGT AND HSCRP: EARLY PREDICTORS OF OXIDATIVE STRESS AND INFLAMMATION IN TYPE 2 DIABETES MELLITUS PATIENTS WITH GOOD AND POOR GLYCEMIC CONTORL

    Nov 1, 2019, 00:00 AM

  • PCN32 COMPARATIVE EFFICACY OF PEMBROLIZUMAB PLUS AXITINIB (P+A) VERSUS FIRST-LINE SYSTEMIC THERAPIES FOR ELDERLY PATIENTS WITH ADVANCED/METASTATIC RCC (MRCC): A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS

    Nov 1, 2019, 00:00 AM

  • PNS221 ANALYSIS OF HTA DOSSIERS SUBMISSION AND RECOMMENDATION REPORTS FOR DRUG PROCUREMENT AND REIMBURSMENT IN UKRAINE

    Nov 1, 2019, 00:00 AM

  • PCV21 TIMI RISK SCORE IN PREDICTING IN HOSPITAL AND EARLY MORTALITY AFTER PRIMARY PERCUTANEOUS CORONARY INTERVENTION IN ELDERLY WOMEN:RESULTS FROM A DEVELOPING COUNTRY

    Nov 1, 2019, 00:00 AM

  • PCN306 THE MODEL OF OUTCOMES-BASED RISK SHARING AGREEMENTS APPLIED TO TARGETED DRUGS IN ONCOLOGY

    Nov 1, 2019, 00:00 AM

  • PCN36 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY: A PROSPECTIVE OBSERVATIONAL STUDY

    Nov 1, 2019, 00:00 AM

  • PMD56 NETWORK META-ANALYSIS OF THE USE OF ISTENT® INJECT MICROINVASIVE SURGERY IN COMBINATION WITH PHACOEMUSIFICATION FOR GLAUCOMA AND CATARACT PATIENTS

    Nov 1, 2019, 00:00 AM

  • PCV87 A REVIEW ASSESSING THE PROPORTION OF HEART FAILURE WITH PRESERVED EJECTION FRACTION PATIENTS AMONGST HEART FAILURE PATIENTS

    Nov 1, 2019, 00:00 AM

  • PGI58 A STUDY OF LONG TERM HOSPITALIZATION COSTS IN PATIENTS WITH ULCERATIVE COLITIS USING GERMAN CLAIMS DATA

    Nov 1, 2019, 00:00 AM

  • Infectious Diseases - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00 AM

  • PSS16 ANTI-VEGF INTRAVITREAL INJECTIONS IN PORTUGAL: THE FIRST DECADE 2007-2017

    Nov 1, 2019, 00:00 AM

  • PSY16 COST-EFFECTIVENESS OF TOFACITINIB IN ACTIVE PSORIATIC ARTHRITIS AFTER CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS TREATMENT IN SPAIN

    Nov 1, 2019, 00:00 AM

  • PCN258 APPLYING BIG DATA ANALYTICS TO DEVELOP PREDICTIVE MODELS FOR ESTIMATING HER2+ BC INCIDENCE AND PREVALENCE IN BRAZIL

    Nov 1, 2019, 00:00 AM

  • PRO39 CONCEPTUAL FRAMEWORK FOR EVALUATING THE COST-EFFECTIVENESS OF A GENE THERAPY FOR HAEMOPHILIA B

    Nov 1, 2019, 00:00 AM

  • Urinary/Kidney Disorders - Real World Data Information Systems

    Nov 1, 2019, 00:00 AM

  • Neurological Disorders - Conceptual Papers (CP)

    Nov 1, 2019, 00:00 AM

  • PIN64 COST OF HEPATITIS C VIRUS ERADICATION: ECONOMIC MODEL CONCEPT

    Nov 1, 2019, 00:00 AM
  • «
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37 (current)
  • 38
  • 39
  • 40
  • »